SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S50 - MS Novel Therapeutics and Animal Models

Event Time: Friday April 28, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
2:35 PM - 3:00 PM Discussion Michael Racke MD 

Disclosures

Speaker Disclosure
Michael K. Racke, MD Dr. Racke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Coherus Bioscience;Teva Neuroscience;. Dr. Racke has received personal compensation in an editorial capacity for Elsevier as Editor-in-Chief of Journal of Neuroimmunology. Dr. Racke has received research support from Genentech; Novartis; Actelion; TG Therapeutics; Alkermes.

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Astrocytic Junctional Adhesion Molecule-A (JAM-A) Promotes CNS Inflammatory Lesion Pathogenesis Candice Chapouly, PhD, PharmD
Disclosure:
Dr. Horng has nothing to disclose.

1:12 PM 002 CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study David Weinstein
Disclosure:
Dr. Weinstein has received personal compensation for activities with InteKrin Therapeutics, Inc. and Coherus BioSciences as a consultant. Dr. Weinstein has received compensation for serving on the Board of Directors and the Scientific Advisory Board of RiverTown Therapeutics, Inc. Dr. Weinstein has received (royalty or license fee or contractual rights) payments from RiverTown Therapeutics Inc.

1:24 PM 003 A high-throughput screen identifies a candidate molecule that promotes remyelination with significant translational potential Kelsey Rankin
Disclosure:
Dr. Rankin has nothing to disclose.

1:36 PM 004 Accelerated cellular senescence in a model of multiple sclerosis Dimitrios Papadopoulos, MD
Disclosure:
Dr. Papadopoulos has received personal compensation for activities with Bayer Hellas, Novartis, Genesis Pharma, and Sanofi-Genzyme as a speaker and for serving on scientific advisory boards.

1:48 PM 005 Serum and CSF Neurofilament Light Levels Predict Long-Term Outcomes in Multiple Sclerosis Patients Jens Kuhle
Disclosure:
Received research support from Bayer (Schweiz) AG, Genzyme, Novartis, Protagen AG, and Roche.

2:00 PM 006 The characterisation of an inducible demyelination zebrafish model to aid the investigation and development of novel therapeutics in multiple sclerosis Alexander McGown, PhD
Disclosure:
Dr. McGown has nothing to disclose.

2:12 PM 007 Fc RI (CD64) Receptors Are Widely Expressed on CNS Neurons and Are Required for Neuronal IgG Binding and Uptake: Implications for Antibody-Mediated Neuronal Injury Suzanne Liu
Disclosure:
Dr. Liu has nothing to disclose.

2:24 PM 008 Investigating the Role of Fibrinogen and Iron in Inflammatory Demyelination Using Combined High-Resolution MRI and Histopathology in marmoset Experimental Autoimmune Encephalomyelitis Nathanael Lee
Disclosure:
Dr. Lee has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?